228 related articles for article (PubMed ID: 22848491)
1. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease.
McFarland KN; Das S; Sun TT; Leyfer D; Xia E; Sangrey GR; Kuhn A; Luthi-Carter R; Clark TW; Sadri-Vakili G; Cha JH
PLoS One; 2012; 7(7):e41423. PubMed ID: 22848491
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide increase in histone H2A ubiquitylation in a mouse model of Huntington's disease.
McFarland KN; Das S; Sun TT; Leyfer D; Kim MO; Xia E; Sangrey GR; Kuhn A; Luthi-Carter R; Clark TW; Sadri-Vakili G; Cha JH
J Huntingtons Dis; 2013; 2(3):263-77. PubMed ID: 25062675
[TBL] [Abstract][Full Text] [Related]
3. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models.
Sadri-Vakili G; Bouzou B; Benn CL; Kim MO; Chawla P; Overland RP; Glajch KE; Xia E; Qiu Z; Hersch SM; Clark TW; Yohrling GJ; Cha JH
Hum Mol Genet; 2007 Jun; 16(11):1293-306. PubMed ID: 17409194
[TBL] [Abstract][Full Text] [Related]
4. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
[TBL] [Abstract][Full Text] [Related]
5. Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.
Guiretti D; Sempere A; Lopez-Atalaya JP; Ferrer-Montiel A; Barco A; Valor LM
Neurobiol Dis; 2016 May; 89():190-201. PubMed ID: 26851501
[TBL] [Abstract][Full Text] [Related]
6. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
Moreno CL; Ehrlich ME; Mobbs CV
Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
[TBL] [Abstract][Full Text] [Related]
7. Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice.
Achour M; Le Gras S; Keime C; Parmentier F; Lejeune FX; Boutillier AL; Néri C; Davidson I; Merienne K
Hum Mol Genet; 2015 Jun; 24(12):3481-96. PubMed ID: 25784504
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.
Jia H; Morris CD; Williams RM; Loring JF; Thomas EA
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E56-64. PubMed ID: 25535382
[TBL] [Abstract][Full Text] [Related]
9. Modulation of nucleosome dynamics in Huntington's disease.
Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
[TBL] [Abstract][Full Text] [Related]
10. Acetylation State of Lysine 14 of Histone H3.3 Affects Mutant Huntingtin Induced Pathogenesis.
Faragó A; Zsindely N; Farkas A; Neller A; Siági F; Szabó MR; Csont T; Bodai L
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499499
[TBL] [Abstract][Full Text] [Related]
11. LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
Chopra V; Quinti L; Khanna P; Paganetti P; Kuhn R; Young AB; Kazantsev AG; Hersch S
J Huntingtons Dis; 2016 Dec; 5(4):347-355. PubMed ID: 27983565
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide ChIP-seq mapping and analysis reveal butyrate-induced acetylation of H3K9 and H3K27 correlated with transcription activity in bovine cells.
Shin JH; Li RW; Gao Y; Baldwin R; Li CJ
Funct Integr Genomics; 2012 Mar; 12(1):119-30. PubMed ID: 22249597
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
Konsoula Z; Barile FA
J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape of transcriptional and epigenetic dysregulation in early onset polyglutamine disease.
Valor LM; Guiretti D; Lopez-Atalaya JP; Barco A
J Neurosci; 2013 Jun; 33(25):10471-82. PubMed ID: 23785159
[TBL] [Abstract][Full Text] [Related]
16. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model.
Rossaert E; Pollari E; Jaspers T; Van Helleputte L; Jarpe M; Van Damme P; De Bock K; Moisse M; Van Den Bosch L
Acta Neuropathol Commun; 2019 Jul; 7(1):107. PubMed ID: 31277703
[TBL] [Abstract][Full Text] [Related]
17. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Sadri-Vakili G; Cha JH
Curr Alzheimer Res; 2006 Sep; 3(4):403-8. PubMed ID: 17017871
[TBL] [Abstract][Full Text] [Related]
19. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease.
Yeh HH; Young D; Gelovani JG; Robinson A; Davidson Y; Herholz K; Mann DM
Brain Res; 2013 Apr; 1504():16-24. PubMed ID: 23419892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
